Results 181 to 190 of about 48,845 (222)
Some of the next articles are maybe not open access.

Sunitinib

Reactions Weekly, 2009
Sunitinib is an oral multikinase inhibitor that blocks the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) alpha and beta, c-kit, and other receptors. These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC) and unresectable gastrointestinal stromal ...
Daniel Y C, Heng   +1 more
openaire   +3 more sources

Sunitinib

Drugs, 2006
Sunitinib and its active metabolite (SU012662) are selective inhibitors of multiple receptor tyrosine kinases associated with tumour growth and angiogenesis. The clinical efficacy of oral sunitinib has been demonstrated in patients with advanced gastrointestinal stromal tumours (GIST).
Emma D, Deeks, Gillian M, Keating
openaire   +2 more sources

Sunitinib malate

Cancer Chemotherapy and Pharmacology, 2006
Recently, there has been a growing interest in understanding the role of receptor tyrosine kinases (RTK), such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), and fms-like tyrosine kinase 3 (FLT3), in promoting tumor angiogenesis, tumor growth and metastasis ...
Hassane, Izzedine   +3 more
openaire   +2 more sources

Final Overall Survival Analysis for the Phase II RECORD-3 Study of First-Line Everolimus Followed by Sunitinib Versus First-Line Sunitinib Followed by Everolimus in Metastatic RCC [PDF]

open access: yesAnnals of Oncology, 2017
Background: RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This
C H Barrios   +2 more
exaly   +2 more sources

Sunitinib

Expert Opinion on Pharmacotherapy, 2007
Sunitinib is a small-molecule inhibitor of several receptor tyrosine kinases relevant to tumor angiogenesis, including the vascular endothelial growth factor (VEGF) receptor. Potent inhibition of this related family of receptors and consequent antiangiogenic effects have been demonstrated in vitro and in murine models. Human studies have established 50
openaire   +2 more sources

Sunitinib and Hypothyroidism

New England Journal of Medicine, 2007
Pascal, Wolter   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy